Dr. Frankel is originally from Austin, Texas and received his initial medical training at Harvard University in Boston, Massachusetts. He completed a research postdoctoral fellowship at the NIH and residency and medical oncology fellowship at Stanford University. He is board certified in hematology and medical oncology and has a strong clinical background in general medical oncology, and benign and malignant hematology. His research focus is the preclinical and clinical development of targeted cancer therapeutics. He leads the Phase 1 Clinical Trials unit at UTSW. Dr. Frankel’s interests outside of medicine include his family, reading, weight training and walking.
- Medical School
- Harvard Medical School (1973)
- Yale School of Medicine (1974), Internal Medicine
- Other Post Graduate Training
- National Institutes of Health-Research (1978), Research
- Stanford School of Medicine (1980), Internal Medicine
- Stanford School of Medicine (1982), Oncology
Recurrent Breast Cancer
- Metastatic Melanoma
Medical Treatment of Cancer
- Biologic Therapy
- Hormonal Therapy
- Targeted Therapy
Medical Treatment of Breast Cancer
- Breast Cancer Therapy & Treatment
- Identification of enrichment biomarkers for response to new cancer drugs
- Phase 1 clinical trials of novel recombinant protein, nucleic acid and small molecule drugs
- Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
- Frankel AE, Zuckero SL, Mankin AA, Grable M, Mitchell K, Lee YJ, Neville DM, Woo JH Curr Drug Targets 2009 Feb 10 2 104-9
- Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.
- Kuo SR, Willingham MC, Bour SH, Andreas EA, Park SK, Jackson C, Duesbery NS, Leppla SH, Tang WJ, Frankel AE Microb. Pathog. 2008 Jun 44 6 467-72
- Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
- Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ Blood 1997 Nov 90 9 3654-61
- Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma.
- Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham MC Biochemistry 1996 Nov 35 47 14749-56
- American Association for Cancer Research (1989)
- American Society of Hematology (1989)
- American Society of Clinical Oncology (1982)